Effects of Inhibition of the Na+/K+/2cl- Cotransporter on Myogenic and Angiotensin Ii Responses of the Rat Afferent Arteriole.
From: Smooth Muscle Research Group, Department of Pharmacology and Therapeutics, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada.
American journal of physiology. Renal physiology
- Publish Date: Mar 2007
- ISSN: 0363-6127
- Volume: 292
- Issue: 3
- Pages: F999-F1006
- Medium: Print
- Language: English
- Citation (JAMA): Wang Xuemei, Breaks Jennifer, Loutzenhiser Kathy, et al. Effects of Inhibition of the Na+/K+/2cl- Cotransporter on Myogenic and Angiotensin Ii Responses of the Rat Afferent Arteriole.. Am. J. Physiol. Renal Physiol. Mar 2007;292:F999-F1006
Abstract
The Na(+)/K(+)/2Cl(-) cotransporter (NKCC) plays diverse roles in the kidney, contributing sodium reabsorption and tubuloglomerular feedback (TGF). However, NKCC is also expressed in smooth muscle and inhibitors of this transporter affect contractility in both vascular and nonvascular smooth muscle. In the present study, we investigated the effects of NKCC inhibitors on vasoconstrictor responses of the renal afferent arteriole using the in vitro perfused hydronephrotic rat kidney. This preparation has no tubules and no TGF, eliminating this potential complication. Furosemide and bumetanide inhibited myogenic responses in a concentration-dependent manner. Bumetanide was approximately 20-fold more potent (IC(50) 1.0 vs. 20 micromol/l). At 100 and 10 micromol/l, furosemide and bumetanide inhibited myogenic responses by 72 +/- 4 and 68 +/- 5%, respectively. The maximal level of inhibition by bumetanide was not affected by nitric oxide synthase inhibition (100 micromol/l N(G)-nitro-l-arginine methyl ester). However, the time course for the dilation was slowed (from t(1/2) = 4.0 +/- 0.5 to 8.3 +/- 1.7 min, P = 0.04), suggesting either a partial involvement of NO or a permissive effect of NO on relaxation kinetics. Bumetanide also inhibited ANG II-induced afferent arteriolar vasconstriction at similar concentrations. Finally, NKCC1, but not NKCC2, expression was demonstrated in the afferent arteriole by RT-PCR and the presence of NKCC1 in afferent arteriolar myocytes was confirmed by immunohistochemistry. In concert, these results indicate that NKCC modulation is capable of altering myogenic responses by a mechanism that does not involve TGF and suggest a potential role of NKCC1 in the regulation of vasomotor function in the renal microvasculature.
Mesh Headings (Keywords): Angiotensin II, Animals, Arterioles, Blood Pressure, Bumetanide, Dose-Response Relationship, Drug, Furosemide, Gene Expression, Kidney Glomerulus, Male, Myocytes, Smooth Muscle, NG-Nitroarginine Methyl Ester, Perfusion, Rats, Rats, Sprague-Dawley, Sodium Potassium Chloride Symporter Inhibitors, Sodium-Potassium-Chloride Symporters, Vasoconstriction, Vasoconstrictor Agents, Vasodilation
Check for Full Text / PubMed Unique Identifier (PMID): 17090779
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.